SPONSOR
Grifols Therapeutics LLC
Total Trials
2
Recruiting
2
Phases
Phase 4, Phase 3
Conditions studied: Von Willebrand DiseaseHypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic LeukemiaMultiple MyleomaNon-Hodgkin Lymphoma
Clinical Trials by Grifols Therapeutics LLC
NCT02472665 Phase 4
Recruiting
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Von Willebrand Disease
NCT05645107 Phase 3
Recruiting
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Hypogammaglobulinemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology